Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 2019-02-06: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2018-08-30: Initial authorization |
== Patient Drug Information== | == Patient Drug Information== | ||
Revision as of 11:02, 8 May 2023
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2019-02-06: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
History of changes in EMA indication
- 2018-08-30: Initial authorization
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi